JP Morgan Chase’s Iovance Biotherapeutics IOVA Stock Holding History

JP Morgan Chase’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,000	Closed	-$207K	–	7559
2024 Q1	$207K	Buy	+14,000	New	+$163K	﹤0.01%	5332
2021 Q4	–	Sell	-75,000	Closed	-$1.85M	–	6793
2021 Q3	$1.85M	Buy	+75,000	New	+$1.77M	﹤0.01%	3847
2020 Q3	–	Sell	-710,100	Closed	-$19.5M	–	5618
2020 Q2	$19.5M	Sell	710,100 -132,400	-16%	-$4.35M	﹤0.01%	1383
2020 Q1	$25.2M	Buy	842,500 +326,300	+63%	+$8.65M	0.01%	1116
2019 Q4	$14.3M	Buy	516,200 +441,200	+588%	+$10M	﹤0.01%	1830
2019 Q3	$1.36M	Buy	+75,000	New	+$1.66M	﹤0.01%	3657

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

JP Morgan Chase's IOVA Position: Q1 2026 in Review

JP Morgan Chase reduced its Iovance Biotherapeutics (IOVA) stake by 17% in Q1 2026, selling an estimated $1.6M and leaving 2,500,624 shares worth $8.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2850.

JP Morgan Chase first reported a position in IOVA in Q4 2015 and has held it in 40 quarters since. The position peaked at $65M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

JP Morgan Chase held 2,500,624 shares of Iovance Biotherapeutics worth $8.3M as of Q1 2026.
JP Morgan Chase sold 500,878 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.6M.
Iovance Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2850 holding.
JP Morgan Chase first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 40 quarters since.
JP Morgan Chase's Iovance Biotherapeutics position peaked at $65M in Q1 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.